Epilepsy Drug Shows Promise for Treating Sleep Apnoea
Research indicates that sulthiame, an epilepsy medication, may effectively reduce symptoms of obstructive sleep apnoea in patients unable to use CPAP machines. The study showed significant improvements in breathing and oxygen levels among participants taking the drug.
| Score | Value |
|---|---|
Scale | 6 |
Novelty | 7 |
Positivity | 7 |
Reliability | 8 |
Actionability | 5 |
Society | 6 |
Journalism | 4 |
Highlights
- A study presented at the European Respiratory Society Congress in Vienna found that the epilepsy drug sulthiame reduced symptoms of obstructive sleep apnoea in patients who could not tolerate CPAP machines.
- The trial involved 298 patients across Europe who were given varying doses of sulthiame or a placebo.
- Patients taking the highest dose of sulthiame experienced a nearly 40% reduction in breathing pauses and improved oxygen levels during sleep.
- Sulthiame is currently unlicensed in the UK but is available in Australia, the US, and other parts of Europe.
- Further research is needed to confirm the long-term effects and potential side effects of sulthiame for treating obstructive sleep apnoea.
Perspectives
- Experts emphasize the necessity for alternative treatments to CPAP machines, as many patients find them difficult to use long-term, highlighting the potential of sulthiame as a viable option.
- While the results are promising, some experts urge caution regarding the long-term effects and side effects of sulthiame, stressing the importance of further research.